Meeting of the Uniform Formulary Beneficiary Advisory Panel, 40730-40731 [2014-16407]

Download as PDF 40730 Federal Register / Vol. 79, No. 134 / Monday, July 14, 2014 / Notices Transmittal No. 14–21 DEPARTMENT OF DEFENSE India—UGM–84L Harpoon Missiles mstockstill on DSK4VPTVN1PROD with NOTICES POLICY JUSTIFICATION Notice of Proposed Issuance of Letter of Offer Pursuant to Section 36(b)(1) of the Arms Export Control Act, as amended Office of the Secretary The Government of India has requested a possible sale of 12 UGM– 84L Harpoon Block II Encapsulated Missiles, 10 UTM–84L Harpoon Encapsulated Training missiles, 2 Encapsulated Harpoon certification training vehicles, containers, spare and repair parts, support and test equipment, personnel training and training equipment, publications and technical data, U.S. Government and contractor engineering and logistics support services, and other related elements of logistics support. The estimated cost is $200 million. This proposed sale will contribute to the foreign policy and national security of the United States by helping to strengthen the U.S.-India strategic relationship and to improve the security of an important partner which continues to be an important force for political stability, peace, and economic progress in South Asia. This Harpoon missile system will be employed on the Indian Navy’s Shishumar class submarine (Type-209) and will provide enhanced capabilities in defense of critical sea lines of communication. India has already purchased Harpoon missiles for integration on Indian Air Force Jaguar aircraft and Indian Navy P–8I maritime patrol aircraft. India will have no difficulty absorbing these additional missiles into its armed forces. This proposed sale of Harpoon missiles will not alter the basic military balance in the region. The principal contractors will be the Boeing Company in St Louis, Missouri; and Delex Systems Inc., in Vienna, Virginia. In accordance with the Indian Defense Procurement Policy, a contractor may be expected to conclude offset agreements with the Government of India but no offset agreement is currently known to have been proposed in connection with this potential sale. Implementation of this proposed sale will not require the assignment of any additional U.S. Government or contractor personnel to India. However, U.S. Government or contractor personnel in-country visits will be required on a temporary basis for program, technical, and management oversight and support requirements for approximately five years. There will be no adverse impact on U.S. defense readiness as a result of this proposed sale. VerDate Mar<15>2010 19:25 Jul 11, 2014 Jkt 232001 Annex Meeting of the Uniform Formulary Beneficiary Advisory Panel Item No. vii AGENCY: (vii) Sensitivity of Technology: 1. The UGM–84L Harpoon Encapsulated Block II missile system is classified Confidential. The Harpoon missile is a non-nuclear tactical weapon system currently in service in the U.S. Navy and in 28 other foreign nations. It provides a day, night, and adverse weather, standoff air-to-surface capability and is an effective AntiSurface Warfare missile. The UGM–84L incorporates components, software, and technical design information that are considered sensitive. The following components being conveyed by the proposed sale that are considered sensitive and are classified Confidential include: a. The Radar Seeker b. The Guidance Control Unit GPS/INS System c. Operational Flight Program Software d. Missile operational characteristics and performance data These elements are essential to the ability of the Harpoon missile to selectively engage hostile targets under a wide range of operations, tactical and environmental conditions. 2. If a technologically advanced adversary were to obtain knowledge of the specific hardware and software elements, the information could be used to develop countermeasures which might reduce weapon system effectiveness or be used in the development of a system with similar or advanced capabilities. 3. A determination has been made that the recipient country can provide the same degree of protection for the sensitive technology being released as the U.S. Government. This sale is necessary in furtherance of the U.S. foreign policy and national security objectives outlined in the Policy Justification. 4. All defense articles and services listed in this transmittal have been authorized for release and export to the Government of India. [FR Doc. 2014–16351 Filed 7–11–14; 8:45 am] BILLING CODE 5001–06–C PO 00000 Frm 00026 Fmt 4703 Sfmt 4703 Assistant Secretary of Defense (Health Affairs), DoD. ACTION: Notice of meeting. The Department of Defense is publishing this notice to announce a Federal Advisory Committee meeting of the Uniform Formulary Beneficiary Advisory Panel (hereafter referred to as the Panel). DATES: Thursday, July 31, 2014, from 9:00 a.m. to 1:00 p.m. ADDRESSES: Naval Heritage Center Theater, 701 Pennsylvania Avenue NW., Washington, DC 20004. FOR FURTHER INFORMATION CONTACT: Col. J. Michael Spilker, DFO, Uniform Formulary Beneficiary Advisory Panel, 7700 Arlington Boulevard, Suite 5101, Falls Church, VA 22042–5101. Telephone: (703) 681–2890. Fax: (703) 681–1940. Email Address: Baprequests@ dha.mil. SUPPLEMENTARY INFORMATION: This meeting is being held under the provisions of the Federal Advisory Committee Act of 1972 (Title 5 United States Code (U.S.C.) Appendix, as amended) and the Government in the Sunshine Act of 1976 (5 U.S.C. 552b, as amended). Purpose of Meeting: The Panel will review and comment on recommendations made to the Director of Defense Health Agency, by the Pharmacy and Therapeutics Committee, regarding the Uniform Formulary. SUMMARY: Meeting Agenda 1. Sign-In 2. Welcome and Opening Remarks 3. Public Citizen Comments 4. Scheduled Therapeutic Class Reviews (Comments will follow each agenda item) a. Osteoporosis Agents b. Nasal Allergy Agents c. Pulmonary-1 Agents d. Designated Newly Approved Drugs in Already-Reviewed Classes e. Pertinent Utilization Management Issues 5. Panel Discussions and Vote Meeting Accessibility: Pursuant to 5 U.S.C. 552b, as amended, and 41 Code of Federal Regulations (CFR) 102–3.140 through 102–3.165, and the availability of space, this meeting is open to the public. Seating is limited and will be provided only to the first 220 people signing-in. All persons must sign-in legibly. E:\FR\FM\14JYN1.SGM 14JYN1 mstockstill on DSK4VPTVN1PROD with NOTICES Federal Register / Vol. 79, No. 134 / Monday, July 14, 2014 / Notices Administrative Work Meeting: Prior to the public meeting, the Panel will conduct an Administrative Work Meeting from 7:00 a.m. to 9:00 a.m. to discuss administrative matters of the Panel. The Administrative Work Meeting will be held at the Naval Heritage Center, 701 Pennsylvania Avenue NW., Washington, DC 20004. Pursuant to 41 CFR 102–3.160, the Administrative Work Meeting will be closed to the public. Written Statements: Pursuant to 41 CFR 102–3.140, the public or interested organizations may submit written statements to the membership of the Panel at any time or in response to the stated agenda of a planned meeting. Written statements should be submitted to the Panel’s Designated Federal Officer (DFO). The DFO’s contact information can be obtained from the General Services Administration’s Federal Advisory Committee Act Database at https://facadatabase.gov/. Written statements that do not pertain to the scheduled meeting of the Panel may be submitted at any time. However, if individual comments pertain to a specific topic being discussed at a planned meeting, then these statements must be submitted no later than 5 business days prior to the meeting in question. The DFO will review all submitted written statements and provide copies to all the committee members. Public Comments: In addition to written statements, the Panel will set aside 1 hour for individuals or interested groups to address the Panel. To ensure consideration of their comments, individuals and interested groups should submit written statements as outlined in this notice; but if they still want to address the Panel, then they will be afforded the opportunity to register to address the Panel. The Panel’s DFO will have a ‘‘Sign-Up Roster’’ available at the Panel meeting for registration on a first-come, first-serve basis. Those wishing to address the Panel will be given no more than 5 minutes to present their comments, and at the end of the 1 hour time period, no further public comments will be accepted. Anyone who signs-up to address the Panel, but is unable to do so due to the time limitation, may submit their comments in writing; however, they must understand that their written comments may not be reviewed prior to the Panel’s deliberation. To ensure timeliness of comments for the official record, the Panel encourages that individuals and interested groups consider submitting written statements instead of addressing the Panel. VerDate Mar<15>2010 19:25 Jul 11, 2014 Jkt 232001 Dated: July 9, 2014. Aaron Siegel, Alternate OSD Federal Register Liaison Officer, Department of Defense. [FR Doc. 2014–16407 Filed 7–11–14; 8:45 am] BILLING CODE 5001–06–P Department of the Army [Docket ID USA–2014–0027] Privacy Act of 1974; System of Records Department of the Army, DoD. Notice to amend two Systems of Records. AGENCY: ACTION: The Department of the Army proposes to amend two systems of records notices, A0027–10cDAJA, Witness Appearance Files and A0027– 60b DAJA, Patent, Copyright, and Data License Proffers, Infringement Claims, and Litigation Files, in its inventory of record systems subject to the Privacy Act of 1974, as amended. These systems locate and provide witnesses to U.S. attorneys conducting trials on behalf of the Department of the Army; and maintain evidence and record of claims and litigation involving Department of the Army concerning patents, trademarks, copyrights, and data; to maintain evidence and record of Department of the Army attempts to use copyrighted material and to receive the copyright owner’s permission for such use; to maintain record and evidence of patent license offers received and investigations and reports pursuant thereto; and to maintain record and evidence of investigations of proposed legislation or bills for private relief. DATES: Comments will be accepted on or before August 13, 2014. This proposed action will be effective on the day following the end of the comment period unless comments are received which result in a contrary determination. SUMMARY: You may submit comments, identified by docket number and title, by any of the following methods: * Federal Rulemaking Portal: https:// www.regulations.gov. Follow the instructions for submitting comments. * Mail: Federal Docket Management System Office, 4800 Mark Center Drive, East Tower, 2nd Floor, Suite 02G09, Alexandria, VA 22350–3100. Instructions: All submissions received must include the agency name and docket number for this Federal Register document. The general policy for comments and other submissions from PO 00000 Frm 00027 Fmt 4703 Sfmt 4703 members of the public is to make these submissions available for public viewing on the Internet at https:// www.regulations.gov as they are received without change, including any personal identifiers or contact information. Mr. Leroy Jones, Jr., Department of the Army, Privacy Office, U.S. Army Records Management and Declassification Agency, 7701 Telegraph Road, Casey Building, Suite 144, Alexandria, VA 22315–3827 or by phone at 703–428–6185. FOR FURTHER INFORMATION CONTACT: DEPARTMENT OF DEFENSE ADDRESSES: 40731 The Department of the Army systems of records notices subject to the Privacy Act of 1974 (5 U.S.C. 552a), as amended, have been published in the Federal Register and are available from the address in FOR FURTHER INFORMATION CONTACT or at the Defense Privacy and Civil Liberties Office Web site at https://dpclo.defense.gov/. The proposed changes to the record systems being amended are set forth in this notice. The proposed amendments are not within the purview of subsection (r) of the Privacy Act of 1974 (5 U.S.C. 552a), as amended, which requires the submission of a new or altered system report. SUPPLEMENTARY INFORMATION: Dated: July 9, 2014. Aaron Siegel, Alternate OSD Federal Register Liaison Officer, Department of Defense. A0027–10cDAJA SYSTEM NAME: Witness Appearance Files (February 1, 1996, 61 FR 3680) CHANGES: Change System ID to read ‘‘A0027– 10c DAJA’’. * * * * * SYSTEM LOCATION: Delete entry and replace with ‘‘Office of the Judge Advocate General, U.S. Army Litigation Division, 9275 Gunston Road, Building 1450, Fort Belvoir, VA 22060–5546.’’ CATEGORIES OF INDIVIDUALS COVERED BY THE SYSTEM: Delete entry and replace with ‘‘Present and former military personnel and government civilian employees requested to appear as witnesses before civil courts, administrative tribunals, and regulatory bodies.’’ * * * * * E:\FR\FM\14JYN1.SGM 14JYN1

Agencies

[Federal Register Volume 79, Number 134 (Monday, July 14, 2014)]
[Notices]
[Pages 40730-40731]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2014-16407]


-----------------------------------------------------------------------

DEPARTMENT OF DEFENSE

Office of the Secretary


Meeting of the Uniform Formulary Beneficiary Advisory Panel

AGENCY: Assistant Secretary of Defense (Health Affairs), DoD.

ACTION: Notice of meeting.

-----------------------------------------------------------------------

SUMMARY: The Department of Defense is publishing this notice to 
announce a Federal Advisory Committee meeting of the Uniform Formulary 
Beneficiary Advisory Panel (hereafter referred to as the Panel).

DATES: Thursday, July 31, 2014, from 9:00 a.m. to 1:00 p.m.

ADDRESSES: Naval Heritage Center Theater, 701 Pennsylvania Avenue NW., 
Washington, DC 20004.

FOR FURTHER INFORMATION CONTACT: Col. J. Michael Spilker, DFO, Uniform 
Formulary Beneficiary Advisory Panel, 7700 Arlington Boulevard, Suite 
5101, Falls Church, VA 22042-5101. Telephone: (703) 681-2890. Fax: 
(703) 681-1940. Email Address: Baprequests@dha.mil.

SUPPLEMENTARY INFORMATION: This meeting is being held under the 
provisions of the Federal Advisory Committee Act of 1972 (Title 5 
United States Code (U.S.C.) Appendix, as amended) and the Government in 
the Sunshine Act of 1976 (5 U.S.C. 552b, as amended).
    Purpose of Meeting: The Panel will review and comment on 
recommendations made to the Director of Defense Health Agency, by the 
Pharmacy and Therapeutics Committee, regarding the Uniform Formulary.

Meeting Agenda

1. Sign-In
2. Welcome and Opening Remarks
3. Public Citizen Comments
4. Scheduled Therapeutic Class Reviews (Comments will follow each 
agenda item)
    a. Osteoporosis Agents
    b. Nasal Allergy Agents
    c. Pulmonary-1 Agents
    d. Designated Newly Approved Drugs in Already-Reviewed Classes
    e. Pertinent Utilization Management Issues
5. Panel Discussions and Vote

    Meeting Accessibility: Pursuant to 5 U.S.C. 552b, as amended, and 
41 Code of Federal Regulations (CFR) 102-3.140 through 102-3.165, and 
the availability of space, this meeting is open to the public. Seating 
is limited and will be provided only to the first 220 people signing-
in. All persons must sign-in legibly.

[[Page 40731]]

    Administrative Work Meeting: Prior to the public meeting, the Panel 
will conduct an Administrative Work Meeting from 7:00 a.m. to 9:00 a.m. 
to discuss administrative matters of the Panel. The Administrative Work 
Meeting will be held at the Naval Heritage Center, 701 Pennsylvania 
Avenue NW., Washington, DC 20004. Pursuant to 41 CFR 102-3.160, the 
Administrative Work Meeting will be closed to the public.
    Written Statements: Pursuant to 41 CFR 102-3.140, the public or 
interested organizations may submit written statements to the 
membership of the Panel at any time or in response to the stated agenda 
of a planned meeting. Written statements should be submitted to the 
Panel's Designated Federal Officer (DFO). The DFO's contact information 
can be obtained from the General Services Administration's Federal 
Advisory Committee Act Database at https://facadatabase.gov/.
    Written statements that do not pertain to the scheduled meeting of 
the Panel may be submitted at any time. However, if individual comments 
pertain to a specific topic being discussed at a planned meeting, then 
these statements must be submitted no later than 5 business days prior 
to the meeting in question. The DFO will review all submitted written 
statements and provide copies to all the committee members.
    Public Comments: In addition to written statements, the Panel will 
set aside 1 hour for individuals or interested groups to address the 
Panel. To ensure consideration of their comments, individuals and 
interested groups should submit written statements as outlined in this 
notice; but if they still want to address the Panel, then they will be 
afforded the opportunity to register to address the Panel. The Panel's 
DFO will have a ``Sign-Up Roster'' available at the Panel meeting for 
registration on a first-come, first-serve basis. Those wishing to 
address the Panel will be given no more than 5 minutes to present their 
comments, and at the end of the 1 hour time period, no further public 
comments will be accepted. Anyone who signs-up to address the Panel, 
but is unable to do so due to the time limitation, may submit their 
comments in writing; however, they must understand that their written 
comments may not be reviewed prior to the Panel's deliberation.
    To ensure timeliness of comments for the official record, the Panel 
encourages that individuals and interested groups consider submitting 
written statements instead of addressing the Panel.

    Dated: July 9, 2014.
Aaron Siegel,
Alternate OSD Federal Register Liaison Officer, Department of Defense.
[FR Doc. 2014-16407 Filed 7-11-14; 8:45 am]
BILLING CODE 5001-06-P

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.